Brokerages Set Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) PT at $24.25

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) has earned a consensus recommendation of “Moderate Buy” from the ten research firms that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, eight have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $24.6250.

Several equities research analysts have issued reports on the stock. Wall Street Zen lowered shares of Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Mizuho boosted their price objective on Amylyx Pharmaceuticals from $21.00 to $24.00 and gave the stock an “outperform” rating in a research note on Monday. Guggenheim increased their price target on shares of Amylyx Pharmaceuticals from $30.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday, June 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a report on Friday, May 8th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $34.00 target price on shares of Amylyx Pharmaceuticals in a report on Monday, June 8th.

Insider Activity

In related news, insider Gina Mazzariello sold 15,000 shares of Amylyx Pharmaceuticals stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $18.32, for a total transaction of $274,800.00. Following the completion of the sale, the insider directly owned 194,090 shares of the company’s stock, valued at $3,555,728.80. The trade was a 7.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 10.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Amylyx Pharmaceuticals

Large investors have recently bought and sold shares of the company. Meeder Asset Management Inc. bought a new stake in shares of Amylyx Pharmaceuticals in the 4th quarter valued at $25,000. KBC Group NV acquired a new stake in Amylyx Pharmaceuticals in the 1st quarter valued at approximately $26,000. California State Teachers Retirement System bought a new stake in shares of Amylyx Pharmaceuticals in the second quarter worth $28,000. Caitong International Asset Management Co. Ltd lifted its position in Amylyx Pharmaceuticals by 954.4% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,859 shares of the company’s stock worth $47,000 after buying an additional 3,493 shares in the last quarter. Finally, BNP Paribas Financial Markets boosted its position in Amylyx Pharmaceuticals by 433.2% during the second quarter. BNP Paribas Financial Markets now owns 7,267 shares of the company’s stock valued at $47,000 after purchasing an additional 5,904 shares during the last quarter. Institutional investors own 95.84% of the company’s stock.

Amylyx Pharmaceuticals Trading Down 0.6%

Shares of AMLX stock opened at $17.59 on Friday. The firm’s fifty day simple moving average is $15.78 and its 200 day simple moving average is $15.14. The firm has a market capitalization of $1.96 billion, a P/E ratio of -11.73 and a beta of -0.20. Amylyx Pharmaceuticals has a 1 year low of $7.48 and a 1 year high of $19.15.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last released its earnings results on Thursday, May 7th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.03). Equities research analysts anticipate that Amylyx Pharmaceuticals will post -1.4 EPS for the current fiscal year.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.